- Related Products
MedEx answers any queries you might have regarding Sprycel-50 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Sprycel 50 mg is a prescription drug intended for the treatment of specific types of leukemia (the cancer of blood cells). Sprycel falls within the group of medications called “kinase inhibitors”. It acts by preventing the activity of proteins stimulating the growth of tumor cells.
The use of Sprycel must be supervised by a health care professional, experienced in the therapy of leukemia.
Sprycel 50 mg should be taken once daily, preferably at the same time. For the treatment of chronic CML, the initial dose must be 100 mg. For advanced stage of chronic myeloid leukemia and for Ph+ ALL, the starting dose is 140 mg. The dosage can be regulated depending on the patient’s reaction to the drug. Keep taking the drug until the worsening of disease or until you become intolerant to the medication. Patients should be controlled during the therapy to test their blood levels of platelets (substance that promote the blood clotting) and neutrocytes (the white blood cells, which attack the infection). You doctor can advise you to reduce the dose or interrupt the treatment if these indicators change, or if you notice specific adverse effects. It is recommended to swallow the pill whole. For additional information, read the summary of product characteristics.
The common initial dose of Sprycel for the treatment of chronic CML is 100 mg taken orally once a day, while the dose for advanced stage of CML or Ph+ ALL is 140 mg taken orally once a day. In kids suffering from chronic CML, the initial dose depends on their body weight.
In the main research of patients with chronic myeloid leukemia, 90% of the patients reacted to the therapy, while their platelet counts and leukocytes came back to normal. In people with advanced stages of CML and in those with acute lymphoblastic leukemia, about 1/3 of the patients demonstrated a full response. Moreover, about 1/3 of the patients in the major researches demonstrated a decline in the number of leukocytes affected with the Philadelphia chromosome. In the further researches, Sprycel 50 mg showed the same measure of efficiency; however, the once-daily dosage caused fewer adverse reactions.